

Product datasheet for **TL303494V**

Lipin 1 (LPIN1) Human shRNA Lentiviral Particle (Locus ID 23175)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Lipin 1 (LPIN1) Human shRNA Lentiviral Particle (Locus ID 23175)
Locus ID:	23175
Synonyms:	PAP1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	LPIN1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001261427 , NM_001261428 , NM_001261429 , NM_145693 , NM_001349199 , NM_001349200 , NM_001349201 , NM_001349202 , NM_001349203 , NM_001349204 , NM_001349205 , NM_001349206 , NM_001349207 , NM_001349208 , NR_146080 , NM_145693.1 , NM_145693.2 , NM_145693.3 , NM_001261429.1 , NM_001261427.1 , NM_001261427.2 , NM_001261428.1 , NM_001261428.2 , BC030537 , BC030537.1 , BC018071 , NM_145693.4 , NM_001261428.3
UniProt ID:	Q14693
Summary:	This gene encodes a magnesium-ion-dependent phosphatidic acid phosphohydrolase enzyme that catalyzes the penultimate step in triglyceride synthesis including the dephosphorylation of phosphatidic acid to yield diacylglycerol. Expression of this gene is required for adipocyte differentiation and it also functions as a nuclear transcriptional coactivator with some peroxisome proliferator-activated receptors to modulate expression of other genes involved in lipid metabolism. Mutations in this gene are associated with metabolic syndrome, type 2 diabetes, acute recurrent rhabdomyolysis, and autosomal recessive acute recurrent myoglobinuria (ARARM). This gene is also a candidate for several human lipodystrophy syndromes. [provided by RefSeq, Mar 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).